Literature DB >> 28755603

Anticholinergic use trends in 14,013 patients with schizophrenia from three national surveys on the use of psychotropic medications in China (2002-2012).

Yun-Ai Su1, Feng Yan2, Qian Li1, Yu-Tao Xiang3, Liang Shu1, Xin Yu1, Yu-Ping Ning4, Ke-Rang Zhang5, Tao Li6, Qi-Yi Mei7, Ke-Qing Li8, Tian-Mei Si9.   

Abstract

Our previous study demonstrated that there have been changes in the patterns of prescription antipsychotic use in China over the period from 2002 to 2012. The aim of this study was to evaluate whether time trends were present for the prescription of anticholinergic medications (ACMs) during the observation period. A total of 14,013 patients with schizophrenia treated in 45 psychiatric hospitals/centers nationwide were surveyed in 2002, 2006 and 2012. Basic socio-demographic and clinical characteristics and the prescription of psychotropic drugs were recorded using a standardized protocol and data collection procedure. The frequency of ACM prescription was 25.9% in the whole sample (29.5%, 21.6%, and 27.4% in 2002, 2006 and 2012, respectively). In addition, different temporal trends were observed across age groups. Multiple logistic regression analysis of the entire sample showed that ACM prescriptions were predicted by females, outpatients, patients receiving high doses of antipsychotic medication, select study years, benzodiazepine users, patients displaying extrapyramidal side effects, as well as antipsychotic prescription patterns. Although there was more widespread use of second-generation antipsychotics over the past decade, the frequency of ACM use only slightly decreased. How to use ACM appropriately is still a therapeutic issue that needs to foster evidence-based prescription practice.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticholinergic medication; Extrapyramidal symptoms; Prescription patterns; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28755603     DOI: 10.1016/j.psychres.2017.07.038

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

1.  CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4.

Authors:  O M Ogundele; C C Lee
Journal:  Brain Res Bull       Date:  2017-11-11       Impact factor: 4.077

2.  Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.

Authors:  Yash B Joshi; Michael L Thomas; David L Braff; Michael F Green; Ruben C Gur; Raquel E Gur; Keith H Nuechterlein; William S Stone; Tiffany A Greenwood; Laura C Lazzeroni; Laura R MacDonald; Juan L Molina; John A Nungaray; Allen D Radant; Jeremy M Silverman; Joyce Sprock; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Neal R Swerdlow; Gregory A Light
Journal:  Am J Psychiatry       Date:  2021-05-14       Impact factor: 19.242

3.  Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review.

Authors:  Rafaella Georgiou; Demetris Lamnisos; Konstantinos Giannakou
Journal:  Front Psychiatry       Date:  2021-12-28       Impact factor: 4.157

4.  Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study.

Authors:  Jia Jun Weng; Li Hua Wang; Hao Zhu; Wen Rong Xu; Yu Mei Wei; Zhi Yang Wang; Wen Juan Yu; Hua Fang Li
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-07       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.